Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 4/20 | 0.45 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.45 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12042986 | 0.84 | IP6K1 (0.59) | ABL1RIN1IP6K1IP6K3IP6K2 | |
| SCHEMBL1366430 | 0.72 | ABL1 (0.55) | ABL1RIN1POLBIP6K1IP6K3 | |
| SCHEMBL1628815 | 0.71 | HRH3 (0.53) | ABL1RIN1IP6K1IP6K3IP6K2 | |
| SCHEMBL5741452 | 0.70 | GABRR1 (0.50) | ABL1RIN1POLBIP6K1IP6K3 | |
| SCHEMBL38666165 | 0.70 | ABL1 (0.36) | ABL1RIN1POLBAKR1C3MET | |
| SCHEMBL415622 | 0.70 | CALM1 (0.50) | POLBHTR2BL3MBTL1MAOBTAAR1 | |
| SCHEMBL649075 | 0.69 | ALDH1A1 (0.46) | POLBHTR2BL3MBTL1TAAR1HRH3 | |
| SCHEMBL8136730 | 0.69 | L3MBTL1 (0.43) | POLBHTR2BL3MBTL1MAOBTAAR1 | |
| SCHEMBL5907152 | 0.69 | BACE1 (0.74) | POLBBACE1 | |
| SCHEMBL3989724 | 0.68 | ABL1 (0.54) | ABL1RIN1POLBNSD2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996041634-A2 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC S.C.R.L. (IT) | 1996-12-27 | — | — | WO | claimed |
| EP-3125894-B1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7928086-B2 | Administering a beta -L-2'-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug therapy of a host infected with a drug-resistant form of HBV that exhibits a mutation at the 552 codon from methionine to valine in the DNA polymerase region | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| CN-100536853-C | beta-L-2' -deoxynucleosides for the treatment of resistant HBV strains and combination therapy | IDENIX CAYMAN LTD (VG) | 2009-09-09 | — | — | CN | disclosed |
| US-7585851-B2 | 3′-prodrugs of 2′-deoxy-β-L-nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1572095-A4 | S-L-2 -DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1296995-B1 | 3'-PRODRUGS OF 2'-DEOXY-BETA-L-NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-10-15 | — | — | EP | disclosed |
| WO-2001096353-A2 | 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-20 | — | — | WO | disclosed |
| CN-1309647-A | Substd. 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions contg. them | NOVIRIO PHARMACEUTICALS LTD (KY) | 2001-08-22 | — | — | CN | disclosed |
| CN-1309647-A | Substd. 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions contg. them | NOVIRIO PHARMACEUTICALS LTD (KY) | 2001-08-22 | — | — | CN | disclosed |
| CN-1309647-A | Substd. 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions contg. them | NOVIRIO PHARMACEUTICALS LTD (KY) | 2001-08-22 | — | — | CN | disclosed |
| EP-1098887-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novirio Pharmaceuticals Limited (KY) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
| WO-1996041634-A3 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH C (IT) | 1997-01-23 | — | — | WO | disclosed |
| WO-1996041634-A2 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC S.C.R.L. (IT) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996041634-A2 | USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN ASSOCIATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM - SARC S.C.R.L. (IT) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996010565-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ISTITUTO SUPERIORE DI SANITA' (IT) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | ABL1 4246/4885RIN1 4253/4885POLB 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.